2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
141
Breast Neoplasms
10
Neoplasm Metastasis
8
Neoplasms
5
Bulbo-Spinal Atrophy, X-Linked
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Prostate Adenocarcinoma
2
Osteoporosis
2
Lower Urinary Tract Symptoms
2
Hirsutism
2
Thrombocytosis
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Sexual Dysfunction, Physiological
1
Recurrence
1
Primary Myelofibrosis
1
Primary Dysautonomias
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
fludarabine
2
Metformin
2
Busulfan
2
thymoglobulin
1
fludarabine phosphate
1
bicalutamide
1
Testosterone
1
Saline Solution
1
Powders
1
Nutrition Assessment
1
Mesna
1
Melphalan
1
Magnetic Resonance Imaging
1
Influenza Vaccines
1
Honey
1
Heparin
1
Gonadotropin-Releasing Hormone
1
Gastric Bypass
1
Exercise
1
Eating
1
Cyclophosphamide
1
Clofarabine
1
Caloric Restriction
1
Antineoplastic Agents
1
Antilymphocyte Serum
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metabolic Diseases
×
bicalutamide
×
Clear all
NCT05647356
2022-12-12
REFUEL PCOS
Royal College of Surgeons, Ireland
Phase NA
Unknown
16 enrolled